Literature DB >> 33970369

Triggering change in stimulation protocols: a matter of oocyte maturation and beyond.

Alexander M Quaas1,2.   

Abstract

Since the birth of Louise Brown, in vitro fertilization (IVF) stimulation protocols have evolved significantly. One particular area of focus has been the process of final oocyte maturation, during which the oocyte gains competence to support fertilization and early embryonic development up to implantation. The field of human assisted reproductive technology (ART) is witnessing increased utilization of GnRH agonists (GnRHa) as trigger agents, in addition to or instead of the traditionally used human chorionic gonadotropin (hCG). Future translational studies will reveal whether oocyte developmental competence, as reflected in live birth outcomes, are not only non-inferior, but also superior with the use of GnRHa as a trigger for both nuclear and cytoplasmic oocyte maturation.

Entities:  

Keywords:  Assisted reproductive technology; Gonadotropin-releasing hormone agonist; Human chorionic gonadotropin; In vitro fertilization; Oocyte maturation; Ovulation trigger

Mesh:

Substances:

Year:  2021        PMID: 33970369      PMCID: PMC8266975          DOI: 10.1007/s10815-021-02223-z

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.357


  14 in total

Review 1.  GnRH analogues--agonists and antagonists.

Authors:  A M Padula
Journal:  Anim Reprod Sci       Date:  2005-08       Impact factor: 2.145

2.  Time to "cool off"? Examining indications for "elective deferred frozen embryo transfer".

Authors:  Alexander M Quaas; Karl R Hansen
Journal:  J Assist Reprod Genet       Date:  2016-10-08       Impact factor: 3.412

Review 3.  Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment.

Authors:  Ali Abbara; Sophie A Clarke; Waljit S Dhillo
Journal:  Endocr Rev       Date:  2018-10-01       Impact factor: 19.871

Review 4.  Kisspeptins in reproductive biology: consensus knowledge and recent developments.

Authors:  Juan Roa; Victor M Navarro; Manuel Tena-Sempere
Journal:  Biol Reprod       Date:  2011-06-15       Impact factor: 4.285

5.  Birth after the reimplantation of a human embryo.

Authors:  P C Steptoe; R G Edwards
Journal:  Lancet       Date:  1978-08-12       Impact factor: 79.321

Review 6.  Pharmacology of medications used for ovarian stimulation.

Authors:  Alexander M Quaas; Richard S Legro
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2018-11-12       Impact factor: 4.690

7.  Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization cycles: a randomized, double-blind, placebo-controlled trial.

Authors:  Julie D Lamb; Shehua Shen; Charles McCulloch; Liza Jalalian; Marcelle I Cedars; Mitchell P Rosen
Journal:  Fertil Steril       Date:  2011-04       Impact factor: 7.329

Review 8.  The use of GnRH antagonists in ovarian stimulation.

Authors:  F Olivennes; J S Cunha-Filho; R Fanchin; P Bouchard; R Frydman
Journal:  Hum Reprod Update       Date:  2002 May-Jun       Impact factor: 15.610

9.  Establishing full-term human pregnancies using cleaving embryos grown in vitro.

Authors:  R G Edwards; P C Steptoe; J M Purdy
Journal:  Br J Obstet Gynaecol       Date:  1980-09

10.  Oocyte competence is independent of the ovulation trigger adopted: a large observational study in a setting that entails vitrified-warmed single euploid blastocyst transfer.

Authors:  Danilo Cimadomo; Alberto Vaiarelli; Cecilia Petriglia; Gemma Fabozzi; Susanna Ferrero; Mauro Schimberni; Cindy Argento; Silvia Colamaria; Maddalena Giuliani; Nicolò Ubaldi; Laura Rienzi; Filippo Maria Ubaldi
Journal:  J Assist Reprod Genet       Date:  2021-03-04       Impact factor: 3.357

View more
  1 in total

1.  From accepting oversight to being overlooked: the devilish details of controlled ovarian stimulation.

Authors:  David F Albertini
Journal:  J Assist Reprod Genet       Date:  2021-09       Impact factor: 3.357

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.